4-di-n-propylaminocyclohexanone | 106332-42-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-di-n-propylaminocyclohexanone
• 英文别名: 4-(dipropylamino)cyclohexanone；4-dipropylaminocyclohexanone；Cyclohexanone, 4-(dipropylamino)-；4-(dipropylamino)cyclohexan-1-one
• CAS: 106332-42-7
• 化学式: C₁₂H₂₃NO
• 分子量: 197.321
• InChiKey: BIZQSKGTYNMQPL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-di-n-propylaminocyclohexanone 在 potassium hydride 、 sodium hydride 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 为溶剂， 反应 2.5h， 生成 methyl 2-(trifluoromethylsulfonyloxy)-5-(dipropylamino)cyclohex-1-ene-1-carboxylate
  参考文献：
  名称：

  Fancy bioisosteres: Synthesis, SAR, and pharmacological investigations of novel nonaromatic dopamine D3 receptor ligands

  摘要：

  Structural variations of the lead compound FAUC 88 led to dopaminergic enynes with an extended pi-system when Pd-catalyzed cross coupling reactions were employed for the key reaction steps. The dienyne 9b displayed substantial affinity for the dopamine receptor subtype D3 and remarkable selectivity over D4. Compared to FAUC 88, the novel fancy bioisostere 9b displayed reduced ligand efficacy. DFT-based conformational analysis of the test compound 9b, including the calculation of diagnostic magnetic shielding properties and their comparison with experimentally derived NMR data, indicated a clear energetic preference for the s-trans geometry of the diene substructure. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2005.04.047
• 作为产物：
  描述：

  3,3-Dimethyl-N,N-dipropyl-1,5-dioxaspiro[5.5]undecan-9-amine 生成 4-di-n-propylaminocyclohexanone
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• Versatile Protecting-Group Free Tetrazolomethane Amine Synthesis by Ugi Reaction
  作者：Pravin Patil、Michel de Haan、Katarzyna Kurpiewska、Justyna Kalinowska-Tłuścik、Alexander Dömling

  DOI：10.1021/acscombsci.5b00189

  日期：2016.3.14

  components. The scope and limitations of this reaction and a structure–reactivity relationship are provided by performing >85 reactions. The primary amine component of the α-amino tetrazole is a versatile starting material for further reactions.

  由于收率低和多副反应，在Ugi反应中使用氨经常会出现问题。在这里，我们报告了在四唑Ugi变体中使用氨，提供了清洁，良好至高收率的反应，尤其是使用酮作为含氧化合物。该反应的范围和局限性以及结构与反应性的关系可通过执行> 85个反应来提供。α-氨基四唑的伯胺成分是用于进一步反应的通用原料。
• PREPARATION PROCESS OF PERFLUOROALKYL COMPOUND WITH MONOHYDROPERFLUOROALKANE AS STARTING MATERIAL
  申请人：KANTO DENKA KOGYO CO., LTD.

  公开号：US20190169107A1

  公开（公告）日：2019-06-06

  A simple production process is provided of a perfluoroalkyl compound that uses monohydroperfluoroalkane as a starting material, the perfluoroalkyl compound being an important intermediate of organic electronic materials, medicine, agricultural chemicals, functional polymer materials and the like. With monohydroperfluoroalkane is reacted a base and then a carbonyl compound to produce an alcohol having a perfluoroalkyl group. For example, potassium hydroxide is made to interact with trifluoromethane, and a reaction with a carbonyl compound is induced to produce an alcohol having a trifluoromethyl group.

  提供了一种简单的生产过程，使用单羟基全氟烷作为起始物质来制备全氟烷基化合物，该全氟烷基化合物是有机电子材料、药物、农药、功能性聚合物材料等的重要中间体。使用单羟基全氟烷与碱反应，再与羰基化合物反应，可以产生具有全氟烷基的醇。例如，可以将氢氧化钾与三氟甲烷相互作用，并诱导与羰基化合物反应，以产生具有三氟甲基基团的醇。
• Synthesis of 6,7,8,9-tetrahydro-<i>N,N</i>-di-<i>n</i>-propyl-1<i>H</i>-benz[g] indol-7-amine, a potential dopamine receptor agonist
  作者：Vassilis J. Demopoulos、Antonis Gavalas、George Rekatas、Ekaterini Tani

  DOI：10.1002/jhet.5570320408

  日期：1995.7

  sulfonamide bond in 10 gave the target compound 1. A byproduct which was isolated was assigned to the structure of 1-(p-toluenesul-fonyl)-6-[3-[1-(p-toluenesulfonyl)]pyrrolyl]indole (11). This compound was also synthesized in good yield by an acid catalyzed dimerization of the dimethyl acetal of 1-(p-toluenesulfonyl)pyrrole-3-acetaldehyde (4). Preliminary screening of 1 indicated that it possesses central dopamine

  在这项工作中，6,7,8,9-四氢-合成N，N- -di - ñ -丙基-1 ħ -苯并[克]吲哚-7-胺（1）进行说明。该化合物被设计为已知多巴胺受体激动剂5-OH-氨基四氢萘2的吲哚生物等排体。合成的关键步骤是在1-（对甲苯磺酰基）吡咯-3-乙醛的二甲基乙缩醛（4）和4-二-正丙基氨基-1-三甲基甲硅烷氧基环己烯（8）之间进行Mukaiyama型羟醛缩合得到1- p甲苯磺酰-6,7,8,9-四氢- N，N-二- ñ -丙基-1-H-苯并[ g ]吲哚-7-胺（10）。裂解10中的磺酰胺键，得到目标化合物1。将分离出的副产物分配给1-（对甲苯磺酰基-芳基）-6- [3- [1-（对甲苯磺酰基）]吡咯基]吲哚的结构（11）。该化合物还通过酸催化1-（对甲苯磺酰基）吡咯-3-乙醛的二甲基乙缩醛（4）以高收率合成。初步筛选1表明其具有中央多巴胺受体激动剂特性。
• Dialkylaminotetrahydroquinazoline
  申请人：Eli Lilly and Company

  公开号：US04622398A1

  公开（公告）日：1986-11-11

  2-Permissibly-substituted-6-dialkylaminotetrahydroquinazolines, receptor agonists.

  2-可替代基-6-双烷基氨基四氢喹唑啉，受体激动剂。
• Chemokine receptor antagonists and use thereof
  申请人：Ono Pharmaceutical Co., Ltd.

  公开号：US08168783B2

  公开（公告）日：2012-05-01

  A compound represented by general formula (I): a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic erythematosus, retinopathy, macular degeneration, pulmonary fibrosis, transplanted organ rejection, etc.), allergic diseases, infections (for example, human immunodeficiency virus infection, acquired immunodeficiency syndrome, etc.), psychoneurotic diseases, cerebral diseases, cardiac/vascular disease (for example, arteriosclerosis, myocardial infarction, stenocardia, cerebral infarction, chronic arterial occlusive disease, etc.), metabolic diseases, and cancerous diseases (for example, cancer, cancer metastasis, etc.), a preventive and/or therapeutic agent for cancerous diseases or infections, or an agent for regeneration therapy.

  化合物的一般式表示为（I）的化合物：其盐，其溶剂化合物或其前药，其中所有符号如规范所定义，具有对CXCR4的拮抗活性，因此可用作预防和/或治疗CXCR4介导的疾病的药物，例如炎症和免疫性疾病（例如类风湿性关节炎，关节炎，系统性红斑狼疮，视网膜病变，黄斑变性，肺纤维化，移植器官排斥等），过敏性疾病，感染（例如人类免疫缺陷病毒感染，获得性免疫缺陷综合症等），心理神经疾病，脑部疾病，心脏/血管疾病（例如动脉硬化，心肌梗塞，心绞痛，脑梗塞，慢性动脉闭塞性疾病等），代谢性疾病和癌症性疾病（例如癌症，癌症转移等），用作预防和/或治疗癌症性疾病或感染的药物，或用作再生治疗剂。